MASS X
1449.00 $
1449.00 $
20
LGD4033
20
MK677
**These statements have not been evaluated by the Food and Drug
administration (FDA). This product is not intended to diagnose, treat,
cure, or prevent any disease.
*All amounts per 1Ml serving
LGD 4033 is a SARM that is more commonly known by the name Ligandrol but has also been called VK5211 or Anabolicum. In various animal studies, LGD 4033 has been shown to increase anabolic activity in the muscles and have positive effects on bone density in male rats experiencing hypogonadism, and have success treating female postmenopausal rats experiencing osteoporosis.
Additionally, various studies presented at the 62nd Annual Meeting of the Gerontology Society of America, found that use with LGD 4033 in animals increased resistance to fracture and bone mineral density after 12 weeks. This increase was noted in cancellous bone after a dose of 0.3 mg/kg per day and noted in cortical bone after a dose of 0.03 mg/kg per day (https://www.sec.gov/Archives/edgar/data/886163/000119312509239917/d425.htm). Furthermore, in both hypogonadal rats and normal rats LGD 4033 use was seen to increase skeletal muscle mass and muscle fiber diameter correlating to contractile power of the muscle which indicates greater muscle strength. In a fascinating study conducted by Roch et. Al, 3-month-old Sprauge-Dawley rats were ovariectomized and given LGD 4033 for 5 weeks. Each rat in the experimental groups was given doses of either 0.04, 0.4 or 4 mg/kg of body weight/day. After use, the researchers conducted an analysis of fiber size, capillary density, and various enzyme levels, additionally, the uterus, gastrocnemius, and soleus muscles were all weighed to document any changes before and after use (https://www.frontiersin.org/articles/10.3389/fendo.2020.556581/full#B30). When determining the effects of the LGD 4033 on the rats, researchers took samples from the quadriceps femoris muscle in order to determine changes in intramuscular fat content. In addition to determining changes in the intramuscular fat content, it was found that with treatment with LGD 4033 there was higher capillary density. Furthermore, with LGD 4033, there was higher activity of the enzyme citrate synthase in the gastrocnemius muscle. It was also found that after testing, the activity of the enzyme lactate dehydrogenase was higher in the longissimus muscle (https://www.frontiersin.org/articles/10.3389/fendo.2020.556581/full#B30). Overall, animal research with LGD 4033 had a uterotrophic effect when subjects were given a 4 mg dosage, beneficial effects on muscle vascularization as well as muscle metabolism were also found following use. Additionally, after the 4 mg dosage of LGD 4033, researchers reported increased muscular weight and increased weight of intramuscular fat content.